Medical Devices & Surgical Technology Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Devices & Surgical Technology Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Fibrosis
Gadolinium-based MRI Contrast Agents Linked to Potentially Fatal Disease Known as Nephrogenic Systemic Fibrosis (NSF). Informational Website and Claims Filing Department Opened by Law Firm to Assist NSF Patients Nationwide
July 22nd, 2007
The U. S. Food and Drug Administration recently warned that a commonly used contrast agent used to improve MRI images has been linked to a potentially fatal disease. Gadolinium-based contrast agents are commonly used to improve the visibility of internal structures when patients undergo an MRI. These contrast agents have been linked to nephrogenic systemic fibrosis (NSF) and nephrogenic fibrosing dermopathy (NFD). These potentially fatal diseases cause thickening of the skin and connective tissues that inhibits their ability to move and may result in broken bones. Other organs are at risk of thickening as well. The Johnson Law Firm, a law firm that represents clients...
Source: Medical Devices & Surgical Technology Week (2007-07-22)
|
